Intended for healthcare professionals

  1. Research
  2. Immune-related adverse...
  3. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
CCBYNC Open access
Research

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis

BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k793 (Published 14 March 2018) Cite this as: BMJ 2018;360:k793

Data supplement

Related articles

See more

Cited by...

  • CD200 immune checkpoint reversal at the site of tumor vaccine inoculation: A novel approach to glioblastoma immunotherapy
  • Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
  • Cascade of immunologic adverse events related to pembrolizumab treatment
  • Immunotherapy causing pneumonitis in a patient with non-small cell lung cancer (NSCLC)
  • Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine
  • CiTE antibody for AML
  • Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Back to top